Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 7 studies | 31% ± 12% | |
myeloid cell | 5 studies | 21% ± 5% | |
endothelial cell | 4 studies | 20% ± 2% | |
microglial cell | 4 studies | 21% ± 4% | |
plasmacytoid dendritic cell | 4 studies | 23% ± 4% | |
mucosal invariant T cell | 3 studies | 17% ± 1% | |
plasma cell | 3 studies | 25% ± 5% | |
epithelial cell | 3 studies | 26% ± 8% | |
lymphocyte | 3 studies | 17% ± 0% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 22% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 2132.45 | 180 / 180 | 100% | 17.05 | 430 / 430 |
stomach | 100% | 1379.39 | 359 / 359 | 100% | 15.43 | 286 / 286 |
uterus | 100% | 1972.87 | 170 / 170 | 100% | 15.44 | 459 / 459 |
esophagus | 100% | 1668.84 | 1444 / 1445 | 100% | 18.10 | 183 / 183 |
breast | 100% | 2157.32 | 459 / 459 | 100% | 15.65 | 1116 / 1118 |
intestine | 100% | 1872.70 | 966 / 966 | 100% | 15.11 | 526 / 527 |
prostate | 100% | 1759.56 | 245 / 245 | 100% | 13.53 | 501 / 502 |
skin | 100% | 2241.98 | 1808 / 1809 | 100% | 14.77 | 471 / 472 |
bladder | 100% | 1827.05 | 21 / 21 | 100% | 14.45 | 502 / 504 |
lung | 100% | 2783.80 | 576 / 578 | 100% | 14.20 | 1151 / 1155 |
thymus | 100% | 1524.28 | 651 / 653 | 99% | 14.16 | 600 / 605 |
kidney | 100% | 1678.73 | 89 / 89 | 98% | 11.91 | 887 / 901 |
pancreas | 98% | 962.69 | 321 / 328 | 100% | 15.90 | 178 / 178 |
liver | 100% | 1213.23 | 226 / 226 | 97% | 8.36 | 395 / 406 |
adrenal gland | 100% | 1227.86 | 258 / 258 | 96% | 9.40 | 220 / 230 |
brain | 91% | 927.76 | 2412 / 2642 | 100% | 13.21 | 705 / 705 |
adipose | 100% | 2476.87 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1990.01 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 24.84 | 29 / 29 |
muscle | 100% | 1943.46 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2920.44 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.83 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 10.20 | 1 / 1 |
peripheral blood | 100% | 5814.06 | 928 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 9.76 | 79 / 80 |
heart | 94% | 1023.12 | 810 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006368 | Biological process | transcription elongation by RNA polymerase II |
GO_0042796 | Biological process | snRNA transcription by RNA polymerase III |
GO_0042795 | Biological process | snRNA transcription by RNA polymerase II |
GO_0045945 | Biological process | positive regulation of transcription by RNA polymerase III |
GO_0032786 | Biological process | positive regulation of DNA-templated transcription, elongation |
GO_0001701 | Biological process | in utero embryonic development |
GO_0032968 | Biological process | positive regulation of transcription elongation by RNA polymerase II |
GO_0015030 | Cellular component | Cajal body |
GO_0016607 | Cellular component | nuclear speck |
GO_0000791 | Cellular component | euchromatin |
GO_0035363 | Cellular component | histone locus body |
GO_0016604 | Cellular component | nuclear body |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0008023 | Cellular component | transcription elongation factor complex |
GO_0019902 | Molecular function | phosphatase binding |
GO_0005515 | Molecular function | protein binding |
GO_0000987 | Molecular function | cis-regulatory region sequence-specific DNA binding |
Gene name | ELL |
Protein name | Elongation factor for RNA polymerase II RNA polymerase II elongation factor ELL (Eleven-nineteen lysine-rich leukemia protein) ELL_HUMAN |
Synonyms | C19orf17 |
Description | FUNCTION: Elongation factor component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Elongation factor component of the little elongation complex (LEC), a complex required to regulate small nuclear RNA (snRNA) gene transcription by RNA polymerase II and III . Specifically required for stimulating the elongation step of RNA polymerase II- and III-dependent snRNA gene transcription . ELL also plays an early role before its assembly into in the SEC complex by stabilizing RNA polymerase II recruitment/initiation and entry into the pause site. Required to stabilize the pre-initiation complex and early elongation. . |
Accessions | U3KQA3 ENST00000262809.9 U3KQ90 ENST00000594635.6 P55199 Q75MS0 ENST00000596124.3 |